CRMP5 antibodies in patients with small-cell lung cancer or thymoma

Cancer Immunology, Immunotherapy

Volumn 57, Issue 2, 2008, Pages 227-232

  Monstad, Sissel E ^a,b   Drivsholm, Lars ^c   Skeie, Geir Olve ^a,b   Aarseth, Jan H ^a,b   Vedeler, Christian A ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c Section of Endocrinology   (Denmark)

Author keywords

CRMP5 antibodies; Immunoprecipitation; ITT; SCLC; Thymoma

Indexed keywords

ANTIBODY; AZATHIOPRINE; COLLAPSIN RESPONSE MEDIATOR PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 5; PREDNISOLONE; PYRIDOSTIGMINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; BLOOD DONOR; CANCER PATIENT; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IN VIVO STUDY; ISOTOPE LABELING; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RAT; SEROLOGY; SERUM; THYMOMA;

ADULT; AGED; ANTIBODIES; CARCINOMA, SMALL CELL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NERVE TISSUE PROTEINS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; THYMOMA; THYMUS NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 36349030247     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0369-1     Document Type: Article

References (18)

1. Roberts WK, Darnell RB (2004) Neuroimmunology of the paraneoplastic neurological degenerations. Curr Opin Immunol 16:616-622
2. Graus F, Dalmau J, Rene R, Tora M, Malats N, Verschuuren JJ, Cardenal F, Vinolas N, Garcia del Muro J, Vadell C, Mason WP, Rosell R, Posner JB, Real FX (1997) Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 15:2866-2872
3. Drlicek M, Bianchi G, Bogliun G, Casati B, Grisold W, Kolig C, Liszka-Setinek U, Marzorati L, Wondrusch E, Cavaletti G (1997) Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. J Neurol 244:85-89
4. Pittock SJ, Kryzer TJ, Lennon VA (2004) Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 56:715-719
5. Monstad SE, Drivsholm L, Storstein A, Aarseth JH, Haugen M, Lang B, Vincent A, Vedeler CA (2004) Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer. J Clin Oncol 22:795-800
6. Monstad SE, Storstein A, Dorum A, Knudsen A, Lonning PE, Salvesen HB, Aarseth JH, Vedeler CA (2006) Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin Exp Immunol 144:53-58
7. Knudsen A, Monstad SE, Dorum A, Lonning PE, Salvesen HB, Drivsholm L, Aarseth JH, Vedeler CA (2006) Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunol Immunother 55:1280-1284
8. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA (2001) CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 49:146-154
9. Storstein A, Monstad SE, Nakkestad HL, Husebye ES, Vedeler CA (2004) Paraneoplastic antibodies against HuD detected by a sensitive radiobinding assay. J Neurol 251:197-203
10. Mygland A, Aarli JA, Matre R, Gilhus NE (1994) Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. J Neurol Neurosurg Psychiatr 57:843-846
11. Falorni A, Nikoshkov A, Laureti S, Grenback E, Hulting AL, Casucci G, Santeusanio F, Brunetti P, Luthman H, Lernmark A (1995) High diagnostic accuracy for idiopathic Addison's disease with a sensitive radiobinding assay for autoantibodies against recombinant human 21-hydroxylase. J Clin Endocrinol Metab 80:2752-2755
12. Falorni A, Ortqvist E, Persson B, Lernmark A (1995) Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 35S or 3H recombinant human ligands. J Immunol Methods 186:89-99
13. Vernino S, Lennon VA (2004) Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res 10:7270-7275
14. Bataller L, Wade DF, Graus F, Stacey HD, Rosenfeld MR, Dalmau J (2004) Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 62:778-782
15. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler C, Verschuuren JJ, Vincent A, Voltz R (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatr 75:1135-1140
16. Dalmau J, Furneaux HM, Cordon-Cardo C, Posner JB (1992) The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol 141:881-886
17. Dalmau J, Graus F, Cheung NK, Rosenblum MK, Ho A, Canete A, Delattre JY, Thompson SJ, Posner JB (1995) Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer 75:99-109
18. Camdessanche JP, Lassabliere F, Meyronnet D, Ferraud K, Absi L, Honnorat J, Antoine JC (2006) Expression of the onconeural CV2/CRMP5 antigen in thymus and thymoma. J Neuroimmunol 174:168-173